Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis

Annals of Allergy, Asthma and Immunology

Volumn 95, Issue 6, 2005, Pages 600-606

  Meltzer, Eli O ^a,b   Hampel, Frank C ^c   Ratner, Paul H ^d   Bernstein, David I ^e,f   Larsen, Lawrence V ^g   Berger, William E ^h,i   Finn Jr , Albert F ^j   Marple, Bradley F ^k   Roland, Peter S ^k   Wall, G Michael ^l   Brubaker, Michael J ^l   Dimas, Carolyn ^l   Potts, Susan L ^l   Silver, Lewis H ^l   Barnes, J Rod ^l  

^a ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c Central Texas Health Research   (United States)

^d Sylvana Research   (United States)

^e Bernstein Clinical Research Center   (United States)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^g Intermountain Clinical Research   (United States)

^h Southern California Research   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^k UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^l ALCON RESEARCH LTD   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

OLOPATADINE; PLACEBO;

ADOLESCENT; ADULT; AGED; ARTICLE; BITTER TASTE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAY FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR PRURITUS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS QUALITY OF LIFE QUESTIONNAIRE; SIDE EFFECT; SNEEZING; SOMNOLENCE;

EID: 28044462601     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61025-3     Document Type: Article

References (14)

1. Salzano FA, d'Angelo L, Motta S, et al. Allergic rhinoconjunctivitis: diagnostic and clinical assessment. Rhinology. 1992;30:265-275.
2. Hollingsworth HM. Allergic rhinoconjunctivitis: current therapy. Hosp Pract (Off Ed). 1996;31:61-62, 65-67, 71-73.
3. Yanni JM, Stephens DJ, Miller ST, et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergy/antihistaminic agent. J Ocul Pharmacol Ther. 1996;12:256-267.
4. Sharif NA, Xu SU, Miller ST, et al. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther. 1996;278:1252-1261.
5. Ohmori K, Hayashi K, Kaise T, et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol. 2002;88:379-397.
6. Miyake K, Horikoshi K, Ikeda Y, Ishii A, Karasawa A. Effects of olopatadine hydrochloride on the increase of histamine and peptide-leukotrienes concentrations in nasal lavage fluid following the antigen-antibody reaction in actively sensitized guinea pigs. Jpn J Pharmacol. 2001;85:453-456.
7. Food and Drug Administration. Guidance for industry: allergic rhinitis: clinical development programs for drug products (draft guidelines). Available at: http://www.fda.gov/cder/guidance/2718dft.htm. Accessed July 7, 2005.
8. Guyatt GH, Kirshner B, Jaeschke R. Measuring health status: what are the necessary measurement properties? J Clin Epidemiol. 1992;45:1341-1345.
9. Juniper EF, Guyatt GH, Jaeschke R. How to develop and validate a new quality of life instrument. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd Ed. New York, NY: Raven Press Ltd; 1995:49-56.
10. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21:77-83.
11. Westfall PH, Tobias RD, Rom D, et al. Concepts and basic methods for multiple comparisons and tests. In: Multiple Comparisons and Multiple Tests Using the SAS System. Cary, NC: SAS Institute Inc; 1999:13-40.
12. Tamura T, Sato H, Miki I, et al. Effects of orally administered olopatadine hydrochloride on the ocular allergic reaction in rats. Allergol Int. 2003;52:77-83.
13. Schoenwetter WF, Dupclay L, Appajosyula S, et al. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin. 2004;20:304-317.
14. Allelock [package insert]. Tokyo, Japan: Kyowa Hakko Kogyo Co Ltd; April 2004.